Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GlycoMimetics Inc GLYC

Healthcare Biotechnology
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of... see more

Recent & Breaking News (NDAQ:GLYC)

GlycoMimetics Poster Shows GMI-1271 Reverses Drug Resistance in Multiple Myeloma Models

Business Wire December 5, 2015

GlycoMimetics Presents at ASH Meeting First-in-Human Data Showing Favorable Safety, Metabolic and Biomarker Profiles for GMI-1271

Business Wire December 5, 2015

Market Update on Movers and Shakers - Research on LMI Aerospace, TriVascular Technologies, Stratus Properties and GlycoMimetics

Accesswire December 1, 2015

GlycoMimetics to Present at Two Investor Conferences in November

Business Wire November 12, 2015

GlycoMimetics Reports Third Quarter 2015 Results

Business Wire November 12, 2015

GlycoMimetics E-selectin and Blood Cancer Data to Be Highlighted at 57th Annual ASH Meeting

Business Wire November 9, 2015

GlycoMimetics, Inc. Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel

Business Wire October 29, 2015

GlycoMimetics Announces Issuance of U.S. Composition of Matter Patent for Drug Candidate GMI-1271

Business Wire August 31, 2015

GlycoMimetics to Present at the Canaccord Genuity Growth Conference

Business Wire August 10, 2015

GlycoMimetics Reports Second Quarter 2015 Results

Business Wire August 6, 2015

GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel

Business Wire June 23, 2015

GlycoMimetics to Present at the Jefferies 2015 Healthcare Conference

Business Wire May 28, 2015

GlycoMimetics Initiates Phase 1/2 Clinical Trial of GMI-1271 as Potential Treatment for Acute Myeloid Leukemia in Combination with Chemotherapy

Business Wire May 19, 2015

FDA Grants Orphan Drug Designation To GlycoMimetics' GMI-1271 For Treatment of Acute Myleogenous Leukemia (AML)

Business Wire May 14, 2015

GlycoMimetics Reports First Quarter 2015 Results

Business Wire May 5, 2015

GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015

Business Wire April 7, 2015

GlycoMimetics to Present First Preclinical Data on E-selectin-CXCR4 Dual Antagonist for Cancer Indications at AACR Annual Meeting 2015

Business Wire March 19, 2015

GlycoMimetics Reports Fourth Quarter and Year-End 2014 Results

Business Wire March 16, 2015

GlycoMimetics Announces Publication of Phase 2 Data for Rivipansel in Sickle Cell Disease

Business Wire March 3, 2015

GlycoMimetics to Present at Two Investor Conferences in March

Business Wire February 26, 2015